The investigation on the synthesis, characterization and anticancer activity of Ru-based chelating diphosphine ligand compounds

Abstract

Compound trans-[RuIII(dmpe)2Cl2]2(PF6)2 (2) (dmpe = 1, 2 - bis (dimethylphosphino) ethane) was obtained by directly reaction of trans-[RuII(dmpe)2Cl2] (1) with [Cp2FeIII(PF6)]. trans-[RuIII(dmpe)2Cl2]2(FeIIIX4)2 (X = Cl, 3; X = Br, 4) were prepared by reaction of compound 1 with FeX3 (X = Cl, Br), respectively. Compounds 2-4 were characterized by IR, electronic absorption spectra, elemental analysis and Single-crystal X-ray diffraction, respectively. Single-crystal X-ray diffraction studies indicate that the ruthenium atoms in compounds 2-4 all define a slightly distorted octahedron with a [RuP4Cl2] coordination core, and the iron atoms in anion FeX4− of compounds 3 and 4 displays the expected tetrahedron with a [FeX4]− coordination core. Both metal-to-ligand charge-transfer (MLCT) and ligand-to-metal charge-transfer (LMCT) transitions exhibit in the lectronic absorption spectra of compounds 2-4. The in vitro activity of compounds 1-4 was evaluated in A549 and HeLa as well as MCF7 cell lines. The relative cell viability of compounds 2-4 on A549, HeLa and MCF7 cancer cells is in the order of 2>3>4 >1 by CCK-8 method. Compounds 2-4 have better activity than that of cisplatin in higher concentration, especially compound 2.